Dong-A Pharmaceutical (President and CEO Won-Bae Kim) debuted Stillen®, a naturally-derived new drug,
in the Philippines in January of this year. Approval was obtained from the Philippine FDA last May, and is now
being prescribed to treat gastric infection. An agreement has been reached with a local partner, Macropharma,
to carry out Post Marketing Surveillance (PMS) at 30 hospitals in Metro Manila.




Dong-A invited 23 leading doctors to Korea to attend a seminar describing the preclinical and clinical trials of
Stillen® on March 25, 2008. The Philippine doctors also attended the Asia Pacific Association for the Study
of the Liver convention, held at COEX in Seoul from March 22 to 26. Dr. Byung-Ok Ahn from the Dong-A
Research Center presented the preclinical findings, and Professor Oh-Yeong Lee of Hanyang University
covered the clinical trials. Information on the development processes and efficacy of the drug was shared
during the Q&A session.




Dong-A Pharmaceutical President and CEO Won-Bae Kim said, “Stillen® is a naturally-derived new drug
with proven efficacy. Exports to China began last year, and we are exploring avenues for introducing the
product to Turkey, Russia and the US,” adding, “We are working hard to make Stillen® a global blockbuster
drug.”






# # #




About Dong-A Pharmaceutical

Dong-A is Korea’s leading pharmaceutical company. Based on its corporate philosophy that the greatest value
is life, Dong-A strives to be a responsible corporate citizen that contributes to the health and welfare of
humankind. Over the past 42 years, Dong-A has maintained a reputation as a trustworthy producer of quality
pharmaceutical products, and has risen to become the number one drug company in Korea. It is expanding its
overseas presence on the strength of its new drug and biopharmaceutical products. Dong-A Socio Group
includes Dong-A Otsuka, a beverage company, and Yongma Logis, a 3PL specialized company, and other
subsidiaries.